US4921838A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Angiogenic and blood perfusion inducing properties of amphiphilic compounds
Assignee: ANGIO-MEDICAL CORP
•
Filing: 1987-06-16
•
Granted: 1990-05-01
•
Expires: 2007-06-16
Abstract
Abstract A method for enhancing angiogenesis and/or blood vascular perfusion in mammals by administering a pharmacologically effective amount of specific angiogenically active non-ionic, anionic, cationic and zwitterionic amphiphilic compounds. An angiogenically effective amount of the angiogenically active compound digitonin is in the range of at least 1.25 microgram to at least 200 microgram of digitonin. The range including enhancement of vascular perfusion is up to 50 mg of digitonin.
Inventors
- 👤 Nicholas Catsimpoolas
- 👤 Ann L. Griffith
- 👤 Robert S. Sinn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-04 23:02
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/66; A61K31/683; A61K31/685; A61K31/13; A61K31/14; A61K31/21; A61K31/56; A61K31/575; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K31/74; A61K31/765
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
61 words
Method for enhancing angiogenesis or vascular perfusion in a mammal comprising: administering an amount of at least one angiogenically active non-ionic amphiphilic compound selected from the group consisting of digitonin, n-octylglucoside, polyoxyethylene p`t`octyl phenol, polyoxyethylene alcohol, n-dodecyl glucoside and dodecyl-beta-D-maltoside to a mammal in need of enhanced angiogenesis or vascular perfusion in an amount sufficient to enhance angiogenesis or vascular perfusion.
Claim 2
Dependent Claim
61 words
Method for enhancing angiogenesis or vascular perfusion in a mammal comprising: administering an amount of at least one angiogenically active non-ionic amphiphilic compound selected from the group consisting of digitonin, n-octylglucoside, polyoxyethylene p`t`octyl phenol, polyoxyethylene alcohol, n-dodecyl glucoside and dodecyl-beta-D-maltoside to a mammal in need of enhanced angiogenesis or vascular perfusion in an amount sufficient to enhance angiogenesis or vascular perfusion.
Claim 3
Dependent Claim
14 words
Method according to claim 1, wherein said non-ionic amphiphilic compound contains a glucoside group.
Claim 4
Dependent Claim
30 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of enhanced angiogenesis an amount of deoxycholic acid or sodium dodecyl sulfate sufficient to enhance angiogenesis.
Claim 5
Dependent Claim
30 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of enhanced angiogenesis an amount of deoxycholic acid or sodium dodecyl sulfate sufficient to enhance angiogenesis.
Claim 6
Dependent Claim
26 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of enhanced angiogenesis an amount of tetradecyltrimethyl-ammonium bromide sufficient to enhance angiogenesis.
Claim 7
Dependent Claim
26 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of enhanced angiogenesis an amount of tetradecyltrimethyl-ammonium bromide sufficient to enhance angiogenesis.
Claim 8
Dependent Claim
42 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of angiogenesis an amount of at least one angiogenically active zwitterionic amphiphilic compound selected from the group consisting of sulfobetaine, 3-[(3-cholamido propyl)dimethylammonio]-1-propanesulphonate and lysophosphatidylcholine sufficient to enhance angiogenesis.
Claim 9
Dependent Claim
42 words
Method for enhancing angiogenesis in a mammal comprising: administering to a mammal in need of angiogenesis an amount of at least one angiogenically active zwitterionic amphiphilic compound selected from the group consisting of sulfobetaine, 3-[(3-cholamido propyl)dimethylammonio]-1-propanesulphonate and lysophosphatidylcholine sufficient to enhance angiogenesis.
Claim 10
Dependent Claim
23 words
Method according to claim 1, wherein said compound is digitonin and is administered in an amount ranging from 1.25 micrograms to 50 mg.
Claim 11
Dependent Claim
56 words
Method according to claim 1 for enhancing vascular blood perfusion in a mammal comprising: administering to a mammal in need of enhanced blood perfusion an amount of at least one angiogenically active non-ionic, or zwitterionic amphiphilic compound selected from the group consisting of digitonin, sulfobetaine, polyoxyethylene glycol sorbitol, N-octylglucoside and dodecyl-beta-D-maltoside, sufficient to enhance vascular perfusion.
Claim 12
Dependent Claim
9 words
Method of claim 7 wherein said compound is digitonin.
References Cited (Backward Citations)
US3975536A
Cited
US4053628A
Cited
US4242502A
Cited
US4511564A
Cited
US4602003A
Cited
US4636497A
Cited
US4681876A
Cited
US4710490A
Cited
US4710490B1
Cited
US4767746A
Cited
US4767746B1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-04-30 | 1993-10-30 | 1994-05-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-04-30 | 1997-10-30 | 1998-05-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-04-30 | 2001-10-30 | 2002-05-01 | $7700.00 | Window Closed / Lapsed |